{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T21:50:26Z","timestamp":1785793826864,"version":"3.56.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009243","name":"Direction G\u00e9n\u00e9rale de l\u2019offre de Soins","doi-asserted-by":"publisher","award":["PHRC-14-0117"],"award-info":[{"award-number":["PHRC-14-0117"]}],"id":[{"id":"10.13039\/501100009243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.isci.2025.113754","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T18:13:52Z","timestamp":1760552032000},"page":"113754","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Use of microbiome analysis as a complementary endpoint in clinical trials"],"prefix":"10.1016","volume":"28","author":[{"given":"Lourdes","family":"Velo-Suarez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles-Antoine","family":"Guilloux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozenn","family":"Le Berre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Gouriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Rault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Mottier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2089-3825","authenticated-orcid":false,"given":"Genevi\u00e8ve","family":"H\u00e9ry-Arnaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2025.113754_bib1","first-page":"135","article-title":"Roscovitine in cancer and other diseases","volume":"3","author":"Cicenas","year":"2015","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.isci.2025.113754_bib2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1021\/ar0201198","article-title":"Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials","volume":"36","author":"Meijer","year":"2003","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.isci.2025.113754_bib3","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000444256","article-title":"Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis","volume":"8","author":"Meijer","year":"2016","journal-title":"J. Innate Immun."},{"key":"10.1016\/j.isci.2025.113754_bib5","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jcf.2021.10.013","article-title":"Safety and pharmacokinetics of Roscovitine (Seliciclib) in cystic fibrosis patients chronically infected with Pseudomonas aeruginosa, a randomized, placebo-controlled study","volume":"21","author":"Meijer","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.isci.2025.113754_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.mimet.2021.106133","article-title":"Implementation of microbiota analysis in clinical trials for cystic fibrosis lung infection: Experience from the OligoG phase 2b clinical trials","volume":"181","author":"Weiser","year":"2021","journal-title":"J. Microbiol. Methods"},{"key":"10.1016\/j.isci.2025.113754_bib7","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jcf.2020.12.002","article-title":"Changes in fecal microbiota with CFTR modulator therapy: A pilot study","volume":"20","author":"Pope","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.isci.2025.113754_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11050350","article-title":"Individual and Group Response of Treatment with Ivacaftor on Airway and Gut Microbiota in People with CF and a S1251N Mutation","volume":"11","author":"Kristensen","year":"2021","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.isci.2025.113754_bib9","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1513\/AnnalsATS.201907-493OC","article-title":"Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation","volume":"17","author":"Harris","year":"2020","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.isci.2025.113754_bib10","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jcf.2020.12.023","article-title":"Extended-culture and culture-independent molecular analysis of the airway microbiota in cystic fibrosis following CFTR modulation with ivacaftor","volume":"20","author":"Einarsson","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.isci.2025.113754_bib11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jcf.2017.08.002","article-title":"Antibiotic exposure and interpersonal variance mask the effect of ivacaftor on respiratory microbiota composition","volume":"17","author":"Peleg","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.isci.2025.113754_bib12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1164\/rccm.201404-0703OC","article-title":"Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis","volume":"190","author":"Rowe","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.isci.2025.113754_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124124","article-title":"Impact of the CFTR-potentiator ivacaftor on airway microbiota in cystic fibrosis patients carrying a G551D mutation","volume":"10","author":"Bernarde","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2025.113754_bib14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40168-020-00810-3","article-title":"Lung function and microbiota diversity in cystic fibrosis","volume":"8","author":"Cuthbertson","year":"2020","journal-title":"Microbiome"},{"key":"10.1016\/j.isci.2025.113754_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-70528-7","article-title":"Cross-talk between airway and gut microbiome links to IgE responses to house dust mites in childhood airway allergies","volume":"10","author":"Chiu","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2025.113754_bib16","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00242-2018","article-title":"Anaerobic bacteria cultured from cystic fibrosis airways correlate to milder disease: a multisite study","volume":"52","author":"Muhlebach","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.isci.2025.113754_bib17","article-title":"Reduced bacterial colony count of anaerobic bacteria is associated with a worsening in lung clearance index and inflammation in cystic fibrosis","volume":"10","author":"O'Neill","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2025.113754_bib18","doi-asserted-by":"crossref","first-page":"D590","DOI":"10.1093\/nar\/gks1219","article-title":"The SILVA ribosomal RNA gene database project: improved data processing and web-based tools","volume":"41","author":"Quast","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.isci.2025.113754_bib19","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/gepi.22065","article-title":"A multivariate distance-based analytic framework for microbial interdependence association","volume":"41","author":"Zhao","year":"2017","journal-title":"Genet. Epidemiol."},{"key":"10.1016\/j.isci.2025.113754_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1009442","article-title":"Multivariable association discovery in population-scale meta-omics studies","volume":"17","author":"Mallick","year":"2021","journal-title":"PLoS Comput. Biol."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004225020152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004225020152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T01:01:23Z","timestamp":1782867683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004225020152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2589004225020152"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2025.113754","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of microbiome analysis as a complementary endpoint in clinical trials","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2025.113754","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"113754"}}